Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOS: Lutein supplementation in AMD and healthy subjects
NCT04761341Phase 4Completed
- Sponsor
- Insel Gruppe
- Start
- Jun 2018
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
Phase 4, open-label trial (2 arms), sponsored by Insel Gruppe. Primary endpoints: Macular Pigment Optical Density at 6 months, Fluorescence Lifetime Imaging Ophthalmoscopy at 6 months and 1 more. Started Jun 2018; status: completed.
Beyond the preview
Go deeper on NCT04761341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761341.